LSL Videos

WHAT'S HAPPENING ON THE FRONT LINES OF COVID-19: A CEO ROUNDTABLE ON TECHNOLOGIES IN DEVELOPMENT FOR THE CURRENT PANDEMIC

• What’s Happening On The Front Lines of COVID-19: A CEO Roundtable On Technologies In Development For The Current Pandemic

  Four biopharma CEOs and cofounders discuss what their organizations are doing to spur the development of diagnostic tests, therapeutics, and vaccines to turn the tide on the COVID-19 pandemic.

• What is XPRIZE Doing To Help In The Battle Of COVID-19?
• The Founding Of COVAXX — A Dedicated COVID-19 Vaccine Company
• The How And Why Behind A CNS Company Pivoting To Develop A Treatment For COVID-19
• What Is Lineage Cell Therapeutics Doing To Tackle COVID-19?
• How The FDA Has Been Able To Adjust To Accelerate COVID-19 Therapeutic Development
• Thoughts On Vaccinating For COVID-19 — Should A Vaccine Be Approved

LEADING THROUGH ADVERSITY: A CEO ROUNDTABLE ON DRUG DEVELOPMENT DURING A PANDEMIC

• Leading Through Adversity: A CEO Roundtable On Drug Development During A Pandemic

  Four biopharma CEOs discuss with Rob Wright, chief editor of Life Science Leader, how they are leading their organizations and conducting drug development during the COVID-19 pandemic.

• How Is The Overall Environment For Development Of Innovative Medicines And Biomedical Technologies?
• Adapting Drug Development During COVID-19
• How Has COVID-19 Stalled Drug Development
• Challenges And Solutions Around Diversity And Inclusion In Clinical Trials During A Pandemic
• The Pandemic As A Catalyst For Drug Development
• Six Minutes On Helping Elected Officials With Win-Win Policy Making

PREPARING FOR THE NEW BIOMANUFACTURING FRONTIER: A FIRESIDE CHAT WITH FLUGEN'S ANDY SKIBO

• Preparing For The New Biomanufacturing Frontier: A Fireside Chat With FluGen’s Andy Skibo

  At the Generis 2020 American Biomanufacturing Summit (July 21 – 23), Andy Skibo, chief manufacturing officer for FluGen, discusses the challenges around developing and delivering a COVID-19 vaccine on a significantly shortened timeframe, plus other opportunities for improving biomanufacturing and its supply chain to support future therapies.

BIOPHARMA AND THE MANAGEMENT OF WALL ST. DURING A PANDEMIC

• Biopharma And The Management Of Wall St. During A Pandemic

  The volatility of the U.S. stock market in the first half of 2020 has even the heartiest investor queasy. But how about the leaders of such publicly traded companies? We conduct a virtual roundtable with three CEOs of publicly traded biopharmaceutical companies to learn how they are leading their organizations while also managing the expectations of Wall Street during the COVID-19 pandemic.

• Taking On Debt And Executing A Public Offering During COVID-19
• Why Chimerix Pivoted To Take On COVID-19
• Managing Clinical Trials And Supply Amidst COVID-19 Outbreak
• Serving Traumatic Injury Patients And Surgeons During Pandemic Panic
• Biopharma CEOs Weigh In On Working With Wall St. During Pandemic Pandemonium
• AxoGen CEO Details Approach To Crisis Management During COVID-19
• Don’t Let Efforts To Solve COVID-19 Capsize Decades Of Drug Development Work
• Navigating The Delivery Of Data Via Virtual Conferences And Meetings

LEADERSHIP DURING COVID-19 — A BIOPHARMA CEO ROUNDTABLE

• Leadership During COVID-19 — A Biopharma CEO Roundtable

  Five biopharmaceutical industry CEOs discuss challenges their company's have faced, along with best practices implemented in managing through the COVID-19 chaos.

• Biopharmaceutical Manufacturing During COVID-19
• Best Practices For Working In The Lab Through COVID-19
• Biopharmaceutical Company Fundraising And Investor Meetings During COVID-19
• When COVID-19 Presses Your Company To Make An R&D Pivot
• Working Remotely In Biopharma During COVID-19